Drug Trial Radar · NCT03913143
A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE)
Last checked: Nov 19, 2026Latest source record: Mar 17, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
36
Actual
Start
Apr 4, 2019
Primary completion
Jan 31, 2022
Study completion Mar 2023
Sponsor
- Lead sponsor
- ProQR TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Apr 12, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 8 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this double-masked, randomized, controlled, multiple-dose study is to evaluate the efficacy, safety, tolerability and systemic exposure of sepofarsen (QR-110) administered via intravitreal injection in subjects with Leber's Congenital Amaurosis (LCA) due to the CEP290 p.Cys998X mutation after 24 months of treatment
Conditions
- Leber Congenital Amaurosis 10
- Blindness
- Leber Congenital Amaurosis
- Vision Disorders
- Sensation Disorders
- Neurologic Manifestations
- Eye Diseases
- Eye Diseases, Hereditary
- Eye Disorders Congenital
- Retinal Disease
Interventions
sepofarsenDrug
RNA antisense oligonucleotide for intravitreal injection
ShamOther
Sham-Procedure (no experimental drug administered)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in BCVATime frame: 12 months
Locations
14 sites in 9 countries. Site status is shown where the registry gives one.
University of Iowa
Iowa City, Iowa
Universitair Ziekenhuis Gent (UZ)
Ghent, Belgium
INRET Clínica/ Santa Casa de Misericórdia de Belo Horizonte
Belo Horizonte, Minas Gerais, Brazil
Federal University of São Paulo - Hospital São Paulo (UNIFESP-HSP)
São Paulo, São Paulo, Brazil
The Hospital for Sick Children - SickKids
Toronto, Ontario, Canada
McGill University Health Centre - Centre for Innovative Medicine
Montreal, Quebec, Canada
Centre de maladies rares CHNO des Quinze Vingt
Paris, France
Hospital Civil de Strasbourg
Strasbourg, France
Justus-Liebig Universität - Department of Ophthalmology
Giessen, Germany
University of Tuebingen - Inst. for Ophthalmic Research
Tübingen, Germany
Eye Clinic University of Campania Luigi Vanvitelli
Naples, Italy
Amsterdam University Medica Center - Locatie AMC
Amsterdam, Netherlands
Het Oogziekenhuis Rotterdam
Rotterdam, Netherlands
Moorfields Eye Hospital - NHS Foundation Trust
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.